Ondansetrom Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetrom Kabi, is a 5-HT3 receptor antagonist presented as an intravenous formulation for injection use. It is used to prevent nausea and vomiting associated with chemotherapy, radiotherapy and postoperative settings.

GNH USA supplies Ondansetrom Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical pathways.

- Chemotherapy-induced nausea and vomiting: prevents and treats nausea and vomiting caused by cytotoxic cancer drugs. - Radiotherapy-induced nausea and vomiting: reduces nausea and vomiting associated with radiation treatment. - Postoperative nausea and vomiting: helps prevent nausea and vomiting after surgical procedures.

Ondansetron may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate headache reported. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Fatigue: general tiredness. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT interval prolongation leading to irregular heart rhythm. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Serotonin syndrome: rare condition with agitation, fever, and muscle rigidity. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or visual disturbances.

When using ondansetron, certain precautions should be observed to ensure safe administration. - Cardiac monitoring: assess baseline ECG in patients with known heart disease or electrolyte imbalance. - Electrolyte balance: correct hypokalaemia or hypomagnesaemia before infusion. - Pregnancy risk: use only if potential benefit justifies potential risk to fetus. - Drug interactions: review concomitant medications that may affect QT interval. - Renal/hepatic impairment: adjust dose or monitor in severe dysfunction. - Store at ambient temperature: keep below 25 °C, protect from light and moisture in original packaging.

Ondansetron can interact with several medicines, influencing its safety or effectiveness.

Major Interactions (Avoid): - Apomorphine: may cause profound hypotension and loss of consciousness. - Certain antiarrhythmics (e.g., amiodarone, quinidine): increase risk of QT prolongation. - Serotonergic agents combined with other serotonergic drugs: risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase drug exposure. - Other QT‑prolonging drugs (e.g., fluoroquinolones, antipsychotics): monitor ECG.